EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta

Winnie Liu iD, Brendan Lee, Sandesh C S Nagamani, Lindsey Nicol, Frank Rauch, Eric T Rush, V Reid Sutton, Eric Orwoll iD

The Journal of Clinical Endocrinology & Metabolism · 16.06.2023 · 108 (7) · 1787-1796

DOI: 10.1210/clinem/dgad035 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 20.01.2023. Verfasst von Winnie Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, Diabetes & Clinical Nutrition, Oregon Health & Science University, Portland, OR 97239, USA. Hauptthemen laut MEDLINE: Bone Density Conservation Agents, Osteogenesis Imperfecta, Fractures, Bone. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, Brittle Bone Disease Consortium, National Center for Advancing Translational Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Osteogenesis imperfecta (OI) is a genetic disorder characterized by increased bone fragility largely caused by defects in structure, synthesis, or post-translational processing of type I collagen. The effectiveness of medications used for fracture reduction in adults with OI is understudied and practice recommendations are not well established. Drugs currently used to improve skeletal health in OI were initially developed to treat osteoporosis. Oral and intravenous bisphosphonates have been shown to improve bone mineral density (BMD) in adults with OI and are commonly used; however, conclusive data confirming fracture protection are lacking. Similarly, teriparatide appears to increase BMD, an effect that seems to be limited to individuals with type I OI. The role of denosumab, abaloparatide, romosozumab, and estradiol/testosterone in adult OI have not been systematically studied. Anti-sclerostin agents and transforming growth factor-beta antagonists are under investigation in clinical trials.

Objective

This review summarizes current knowledge on pharmacologic treatment options for reducing fracture risk in adults with OI.

Methods

A PubMed online database search of all study types published in the English language using the terms “osteogenesis imperfecta,” “OI,” and “brittle bone disease” was performed in June 2022. Articles screened were restricted to adults. Additional sources were identified through manual searches of reference lists.

Conclusion

Fracture rates are elevated in adults with OI. Although clinical trial data are limited, bisphosphonates and teriparatide may be useful in improving BMD. Further research is needed to develop medications for adults with OI that will lead to definite fracture rate reduction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone Density Conservation AgentsOsteogenesis ImperfectaFractures, BoneAdultHumansTeriparatideDiphosphonatesBone DensityFracture Fixation

Stichwörter der Autor:innen

abaloparatidebisphosphonatebone mineral densitybrittle bone diseasedenosumabfracturesosteogenesis imperfectarare bone diseaseromosozumabteriparatide

Substanzen

Bone Density Conservation AgentsTeriparatideDiphosphonates

Autor:innen und Institutionen

  • Department of Medicine, Division of Endocrinology, Diabetes & Clinical Nutrition, Oregon Health & Science University, Portland, OR 97239, USA.
  • Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
  • Texas Children's Hospital, Houston, TX 77030, USA.
  • Department of Pediatrics, Division of Endocrinology, Oregon Health & Science University, Portland, OR 97239, USA.
  • Shriners Hospital for Children, Montreal, Quebec H3G 1A6, Canada.
  • Children's Mercy Hospital, University of Missouri-Kansas City, Kansas City, MO 64108, USA.

ORCID-Profile: Winnie Liu, Eric Orwoll

Förderung

  • NIAMS NIH HHS
  • Brittle Bone Disease Consortium
  • National Center for Advancing Translational Science

Zitieren

APA

Liu, W., Lee, B., Nagamani, S. C. S., Nicol, L., Rauch, F., Rush, E. T., Sutton, V. R., & Orwoll, E. (2023). Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta. The Journal of Clinical Endocrinology & Metabolism, 108(7), 1787-1796. https://doi.org/10.1210/clinem/dgad035

Vancouver

Liu W, Lee B, Nagamani SCS, Nicol L, Rauch F, Rush ET, et al. Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta. The Journal of Clinical Endocrinology & Metabolism. 2023;108(7):1787-1796. doi:10.1210/clinem/dgad035

BibTeX
@article{Liu2023,
  author = {Liu, Winnie and Lee, Brendan and Nagamani, Sandesh C S and Nicol, Lindsey and Rauch, Frank and Rush, Eric T and Sutton, V Reid and Orwoll, Eric},
  title = {Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  volume = {108},
  number = {7},
  pages = {1787--1796},
  doi = {10.1210/clinem/dgad035}
}
Kostenlos starten →